Table 2.

Adverse events following immunization with CoronaVac followed by ChAdOx1 nCoV-19 (Oxford-AstraZeneca) in the systemic autoimmune rheumatic diseases (SARDs) group and the healthy group.

Adverse events	Total	SARDs	Healthy group	P value
	N = 60 (%)	n = 30 (%)	n = 30 (%)
CoronaVac	16 (26.7)	10 (33.3)	6 (20)	0.381
Systemic reactions	12 (20.0)	8 (26.7)	4 (13.3)	0.333
Fever	6 (10.0)	5 (15.6)	1 (3.3)	0.197
Chill	1 (1.7)	1 (3.1)	0 (0)	1
Fatigue	3 (5.0)	2 (6.7)	1 (3.3)	1
Myalgia	2 (3.3)	2 (6.2)	0 (0)	0.492
Headache	1 (1.7)	0 (0.0)	1 (3.3)	1
Local reactions	11 (18.3)	5 (16.7)	6 (20.0)	1
Pain	9 (15.0)	4 (13.3)	5 (16.7)	1
Swelling	1 (1.7)	0 (0)	1 (3.3)	0.484
Erythema	1 (1.7)	0 (0)	1 (3.3)	0.484
Nodule	1 (1.7)	1 (3.2)	0 (0)	1
ChAdOx1 nCoV-19	43 (71.7)	21 (70.0)	22 (73.3)	1
Systemic reactions	35 (58.3)	17 (56.7)	18 (60.0)	0.1
Fever	33 (55.0)	17 (56.7)	16 (53.3)	1
Chill	7 (11.7)	2 (6.7)	5 (16.7)	0.424
Fatigue	4 (6.7)	4 (13.3)	0 (0)	0.112
Myalgia	13 (21.7)	6 (20.0)	7 (23.3)	1
Headache	3 (5.0)	2 (6.7)	1 (3.3)	1
Local reactions	29 (48.3)	15 (50)	14 (46.7)	1
Pain	28 (46.7)	15 (50)	13 (43.3)	0.796
Swelling	1 (1.7)	1 (3.3)	0 (0)	1
Erythema	0 (0)	0 (0)	0 (0)	1
Nodule	2 (3.3)	2 (6.7)	0 (0)	0.492

SARDs systemic autoimmune rheumatic diseases.